Aarti Drugs Ltd (AARTIDRUGS)

📊 Quarterly Results (₹ Cr)

Operational momentum is accelerating, with consecutive quarters showing improving operating leverage: OPM rose to 11.3% in June 2026 from 6.2% in December 2025, and 10.8% in March 2026. Revenue growth of 19% YoY in Q1 FY27 was broad-based, with EBITDA growth outpacing revenue, signaling better cost control and scale benefits. PAT margin expansion to 9.9% reflects both operational efficiency and normalization after a one-time tax refund in the prior year (filed 2026-08-01). Capacity additions and backward integration are expected to drive 10-15% volume growth over the next two years, supporting margin targets of 14-15% EBITDA by year-end.

🔮 Management Outlook & What's Next

Management expects sustained demand resilience and plans capacity expansion to improve operating leverage, targeting 10-15% volume growth over the next two years and 14-15% EBITDA margin by year-end (Q1 FY27 filing, 2026-08-07). The leadership transition, with Rashesh Gogri elevated to Chairman and Adhish Patil appointed as Managing Director (effective 2026-10-01), is positioned to support long-term growth in manufacturing and R&D. No formal financial guidance beyond margin and volume targets was provided, but operational visibility appears improving.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows stable capital structure with borrowings held at ₹577 crores as of March 2026, down slightly from ₹612 crores a year ago, while equity and reserves have grown steadily. Total assets increased to ₹2,815 crores, supporting expansion plans without aggressive leverage. Reserves rose to ₹1,458 crores, indicating retained earnings are being reinvested or accumulated, which aligns with growth capex needs. The debt-to-equity ratio of 0.45 remains conservative, suggesting prudent capital allocation with room for strategic investments.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding has remained stable around 54-55% over the past four quarters, indicating confidence in long-term prospects. In contrast, FII and DII ownership have shown mixed trends: FII shareholding rose slightly to 1.52% in Q1FY27 from 1.58% in Q4FY26 (but fell from 2.69% in Q3FY26), while DII increased to 10.29% from 10.12% in Q3FY26. Public holding has gradually increased, and the total number of shareholders has grown to 1.43 lakh, suggesting retail participation is rising. No significant promoter pledging or exit signals are visible.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Execution risk around backward integration completion at Sayakha by December, which is critical for cost control and margin targets. 2. Dependence on export markets, particularly the US, which exposes the company to geopolitical and regulatory volatility despite USFDA approvals. 3. Leadership transition may introduce execution uncertainty if integration of new roles is not seamless, especially in R&D and global operations.

📋 Recent Filings

• 🟡 Board Meeting2026-09-26Aarti Drugs held its 41st AGM on September 26, 2026 via video conference with 93 shareholders present. The meeting covered approval of audited financi…
• 🟡 Board Meeting2026-09-26Aarti Drugs announced board changes at its September 26, 2026 AGM: Uday Patil retired as Whole-time Director, Nilesh Patil was appointed as Whole-time…
• 🟡 voting results2026-09-26At the 41st AGM on September 26, 2026, shareholders approved all 16 resolutions with overwhelming majorities, including the appointment of directors, …
• 🟡 Board Meeting2026-09-26Aarti Drugs reported consolidated revenue of Rs. 2,568 crores for FY26, up 7% from Rs. 2,403 crores in FY25, with PAT rising 16% to Rs. 312 crores. EB…
• 🔴 annual report2026-09-02No summary available
• 🟡 Board Meeting2026-09-02No summary available
• 🟡 sustainability report2026-09-02Aarti Drugs Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26 to BSE and NSE on September 2, 2026, as mandated un…
• 🟡 Board Meeting2026-08-27The board approved the Aarti Drugs Limited Performance Stock Option Plan 2026, authorizing up to 800,000 stock options for eligible employees, subject…
• Board Meeting2026-08-24Aarti Drugs Limited announced its board will meet on August 27, 2026, to approve the Performance Stock Option Plan 2026 and related matters, with trad…
• Announcement2026-08-14Aarti Drugs Limited announced its upcoming investor meetings scheduled for August 20, 2026, from 1:00 PM to 6:00 PM at Systematix in Mumbai, inviting …

🧠 Analyst's Read

Aarti Drugs is demonstrating consistent operational improvement with margin expansion and capacity-led growth, supported by favorable regulatory outcomes and leadership continuity. Investors should monitor execution of backward integration, USFDA product launches, and volume growth trends over the next two years as key catalysts.

Based on filing content and financial data. Not a recommendation.